CA
AST

Corrado Advisors’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Corrado Advisors’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-17,700
Closed -$63K – 126
2017
Q2 		$63K Buy
+17,700
New +$58.3K 0.03% 114

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Corrado Advisors's AST Position: Q3 2017 in Review

Corrado Advisors sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q3 2017, closing a stake of 17,700 shares — an estimated $63K sold.

Corrado Advisors first reported a position in AST in Q2 2017 and held it in 1 quarter. The position peaked at $63K in Q2 2017. 62 funds tracked by Wall St. Rank hold AST as of Q3 2017.

  • Corrado Advisors reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q3 2017 after selling out during the quarter.
  • Corrado Advisors sold 17,700 Asterias Biotherapeutics Inc. Series A shares in Q3 2017, an estimated $63K.
  • Corrado Advisors first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2017 and held it in 1 quarter.
  • Corrado Advisors's Asterias Biotherapeutics Inc. Series A position peaked at $63K in Q2 2017.
  • 62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q3 2017.

Based on Corrado Advisors's 13F filing for Q3 2017, filed 6 Oct 2017.